Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Jun 7;23(1):e0203.
doi: 10.1097/CLD.0000000000000203. eCollection 2024 Jan-Jun.

Increasing pharmacoequity for people with cirrhosis

Melanie A Hundt  1   2 , Ani A Kardashian  1   2
Affiliations
Review

Increasing pharmacoequity for people with cirrhosis

Melanie A Hundt et al. Clin Liver Dis (Hoboken). .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Ani A. Kardashian advises Gilead. The remaining author has no conflicts to report.

Figures

FIGURE 1
FIGURE 1
Areas of inequity in medication access along the therapeutic continuum. Abbreviations: MASH, metabolic dysfunction-associated steatohepatitis; ALD, alcohol- associated liver disease; HCC, hepatocellular carcinoma; PBC, primary biliary cholangitis.
FIGURE 2
FIGURE 2
Solutions to address disparities in access to pharmacotherapies in people with liver disease. Abbreviations: CLD, chronic liver disease; ECHO, extension for community healthcare outcomes; EMR, electronic medical record.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Thomson MJ, Lok AS, Tapper EB. Optimizing medication management for patients with cirrhosis: Evidence-based strategies and their outcomes. Liver Int. 2018;38:1882–1890. - PMC - PubMed
    1. Essien UR, Dusetzina SB, Gellad WF. A policy prescription for reducing health disparities-achieving pharmacoequity. JAMA. 2021;326:1793–1794. - PubMed
    1. Tapper EB, Essien UR, Zhao Z, Ufere NN, Parikh ND. Racial and ethnic disparities in rifaximin use and subspecialty referrals for patients with hepatic encephalopathy in the United States. J Hepatol. 2022;77:377–382. - PubMed
    1. Ahn JC, Lauzon M, Luu M, Noureddin M, Ayoub W, Kuo A, et al. . Racial and ethnic disparities in early treatment with immunotherapy for advanced HCC in the United States. Hepatology. 2022;76:1649–1659. - PubMed
    1. Thompson WW, Symum H, Sandul A, Gupta N, Patel P, Nelson N, et al. . Vital signs: Hepatitis C treatment among insured adults—United States, 2019–2020. MMWR Morb Mortal Wkly Rep. 2022;71:1011–1017. - PMC - PubMed